Parenteral Drugs (India) Ltd.
Snapshot View

4.87 ▼0%

19 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.pdindia.com
Financial Indicators
Market Cap 14.88 Cr.
Earnings per share (EPS) -40.82 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share -253.24 Trailing Twelve Months Ending 2021-03
Price to Book Value -0.02 Calculated using Price: 4.99
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 2.98 Cr. 29,816,300 Shares
FaceValue 10
Company Profile

Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. Over the years, its path breaking innovation has led not only to lower costs but better quality as well because PDPL firmly believes that better quality dose not necessarily mean higher price, it can also be achieved by indigenous techniques and innovative technologies.

Commencing with production of I.V. fluids in polypropylene bottles for the first time ever, as against glass, PDPL has followed up the success in creating single use disposable eye drop It is now set to bring dialysis within the reach of the common man with its innovatively and indigenously made CAPD kits . The company went for a successful public issue in 1994. Using money merely as means to achieve an end, the company has very judiciously applied it to shape out to a reality from the blue print of the dreams of carefully identified areas of potent niche activities. A cost-effective technology at work is evident in every area of its varied production processes. In fact this is one of the rare companies which showcases the use of most modern state-of-the-art technologies co-existing in harmonious synergy with the labor intensive technologies and retained in larger societal interests.

Parenteral Drugs (India)  believes in appropriate and systematic methods and observes highest standard in  letter and spirit. Parenteral Drugs (India)’s quality standards are  truly  high. The company follows a stringent quality control policy, indeed takes quality control measures at every stage of the manufacturing process. The quality assurance department has a well equipped laboratory with most modern testing instrument. The quality policy has resulted in company being conferred upon the ISO 9001:2000 and WHO GMP certification by international bodies. Not just to the products at PDPL quality is pertinent to to every aspect pre-delivery service, delivery and post delivery service. It is a part of the people's attitude in every step from administration production to distribution.

PDPL is the pioneer company making 400 mg Ciprofloxacin infusion in 200 ml with 5% dextose. The I.V. fluids are packed in size ranging from 100 ml to 3 litre and dialysis solution up to 10 litres water for injection is manufactured with the help of hi-tech From-Fill-seal machine ranging from 1 ml to 10 ml.

Products manufactured by the company includes:

Solid and liquid orals

  • ANTIBIOTICS AND ANTIBACTERIAL
  • ANTIULCERANT
  • ANALGESICS ANTI-INFLAMMATORY
  • MULTIVITAMINS AND MINERALS
  • ANXIOLYTIC
  • ANTIPROTOZOAL
  • ANTICOLD
  • ANTHELMINTIC
  • ANTI-HISTAMINIC
  • MUSCLE RELAXANT
  • CARDIAC
  • ANTIDIABETIC
  • COUGH SYRUP
  • Appetite Enhancer

Injections

1. IV Fluids

  • Electrolytes
  • Antibacterial
  • Energy replenisher
  • Irrigation solution
  • Osmotic diuretic
  • Dialysis solution

2. Eye/ear drops

  • Cigram Drops
  • Gentate Drops
  • Gentate - B Drops
  • Ocuroid Drops
  • Flufen Eye Drops
  • Ikleen Eye Drops

Achievements/ recognition

  • The International Gold Awards.
  • The Udyog Ratna.
  • The company has recently achieved a major break-through in designing CAPD kits for patients with terminal renal failure.
  • Introduction of Ciprofloxacin 400 mg infusion in 200 ml with 5% Dextrose for the first time in our country.

Milestones

  • 1975- Founds Prem Pharmaceuticals (Leader in glass-filled I.V. fluids)
  • 1983- Establishes PDPL (Pioneering Leader in Polypropylene-filled I.V.fluids).
  • 1994- Successful public issue.
  • 1996-Launched First single Use Eye/Ear drop Dispensers using  FFS  technology
  • 1997- Establishes Royal Crystal Pvt. Ltd. [now Diamond Crystal-The only one to  make full lead Crystal Glassware in India]
  • 1998- Launched branded products in Tablets/Capsules/Liquids Orals/I.V.
  • 1998-Establishes Punjab Formulations.
  • 2001-Launched CAPD-the dialysis kit that's affordable by common man and is  superior to the import one.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
-4.88%
1 Month
-0.20%
3 Month
+33.42%
6 Month
+94.80%
1 Year
+94.80%
2 Year
+26.49%
5 Year
-85.33%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -18.43 -44.85 -23.61 -46.67 -152.43
Return on Capital Employed (%) -0.02 -5.15 1.90 -2.29 -8.13 -6.91 -5.55 -35.07 -52.31
Return on Assets (%) -6.65 -12.80 -5.44 -8.41 -12.60 -12.16 -13.17 -23.45 -26.72

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 349 246 202 127 325 -17 -136 -447 -561
Non Curr. Liab. 246 427 456 427 440 462 370 4 -26
Curr. Liab. 254 162 166 230 300 428 593 878 1,006
Minority Int. 1 1 1 1 1 0 0 0 0
Equity & Liab. 850 835 825 785 1,066 872 827 435 419
Non Curr. Assets 630 629 619 549 902 750 727 368 351
Curr. Assets 201 192 200 235 163 122 99 67 67
Misc. Exp. not W/O 18 14 5 1 1
Total Assets 850 835 825 785 1,066 872 827 435 419

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 333 327 274 263 260 230 224 32 32
Other Income 0 0 61 1 2 6 2 1 0
Total Income 333 328 334 264 262 236 226 33 32
Total Expenditure -319 -341 -350 -248 -296 -252 -225 -50 -47
PBIDT 14 -14 -15 15 -34 -17 0 -16 -14
Interest -48 -56 -60 -70 -70 -86 -98 -96 -110
Depreciation -14 -23 -19 -31 -23 -25 -24 -69 -17
Taxation -5 -15 1 19 10 10 10 33 28
Exceptional Items 47 0 -1 0
PAT -53 -108 -45 -68 -117 -118 -112 -148 -114

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 20 -168 -60 2 58 134 167 477 112
Cash Fr. Inv. -147 -18 33 3 -110 -1 -1 97 0
Cash Fr. Finan. 133 182 25 -10 54 -134 -167 -574 -112
Net Change 5 -3 -2 -5 1 0 0 0 0
Cash & Cash Eqvt 13 11 8 3 5 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 73.28 73.28 73.28 73.28 73.28 73.28 73.28 73.28 73.28
Public 26.72 26.72 26.72 26.72 26.72 26.72 26.72 26.72 26.72
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 100.00 100.00 100.00 100.00 100.00 100.00 94.51 94.51 94.51

Announcements View Details

Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Parenteral Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Sat, 17 Jul 2021
Corrigendum To Financial Results For The Year Ended 31St March 2021
Parenteral Drugs (India) Limited hereby submits Corrigendum to Financial Results already submitted for the year ended 31st March 2021
Fri, 16 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Parenteral Drugs (India) Limited hereby submits confirmation certificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2021

Technical Scans View Details

Mon, 19 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Stochastic In Overbought Zone Stochastic In Overbought Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%